Developing transformative therapies targeting cancer

Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.

Recent News

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma MORE
  • Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference MORE
  • Seattle Genetics Reports Second Quarter 2018 Financial Results MORE

VIEW ALL NEWS

$77.76

 1.24 (1.57%)

09/21/18  4:00 p.m. ET

NASDAQ | SGEN (Common Stock)

High$79.34
Volume1,776,355
Low$76.80
Mkt Cap$12,347,625,640

Data provided by Nasdaq. Minimum 15 minutes delay

Seattle Genetics Fast Facts

NASDAQSGEN

Common Stock CUSIP812578 102

Fiscal Year Jan. 1 - Dec. 31

State IncorporatedDelaware

Transfer Agent Computershare

STAY CONNECTED

Investor Contact

Peggy Pinkston
Vice President, Investor Relations
investors@seagen.com
425-527-4160

Email Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Get email alerts